A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients

Human Reproduction

Volumn 21, Issue 1, 2006, Pages 95-103

  Rombauts, Luk ^a,d   Healy, David ^a,d   Norman, Rob J ^b   Speirs, A ^c   Watkins, B ^e   Yovich, J ^f   Norman, R ^b   Bowman, M ^g   Driscoll, G ^h   Lindenberg, S ⁱ   Kilani, Z ⁱ   Dale, P O ⁱ   Oddens, B J ^j   van Hooren, H G ^k   Mannaerts, B M J L ^k  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MELBOURNE IVF   (Australia)

^d MONASH IVF   (Australia)

^e Tasmania IVF   (Australia)

^f PIVET Medical Centre   (Australia)

^g Sydney IVF   (Australia)

^h IVFAustralia   (Australia)

ⁱ City West IVF ^*

^j Organon (Australia) Pty Limited   (Australia)

^k NV ORGANON   (Netherlands)

more..

Author keywords

Antagonist; Ganirelix; GnRH agonist; IVF; Nafarelin; Oral contraceptive pretreatment

Indexed keywords

CHORIONIC GONADOTROPIN; DESOGESTREL PLUS ETHINYLESTRADIOL; GANIRELIX; GONADORELIN ANTAGONIST; NAFARELIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; SEX HORMONE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUMULUS OOPHORUS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EMBRYONAL TISSUE; FEMALE; FERTILIZATION IN VITRO; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY CYST; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 29144499138     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei302     Document Type: Article

References (17)

1. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K and Devroey P (2000) Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 15,526-531.
2. Borm G and Mannaerts B; European Orgalutran Study Group (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Hum Reprod 15,1490-1498.
3. Devroey P, Abyholm T, Diedrich K, de Jong D, Hillensjo T, Hedon B, Itskovitz-Eldor J, Kahn J, Naether O, Olivennes F et al (1998) A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon™). Hum Reprod 13, 3023-3031.
4. Doody KJ, Langley M, Marek D and Doody K (2001) Oral contraceptive pretreatment for IVF cycles employing recombinant FSH and a GnRH antagonist. Abstract no. P-373. Fertil Steril 76(3 Suppl 1), S236.
5. Filicori M (1999) The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 71,405-414.
6. Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, Parmegiani L, Pelusi G and DeAloysio D (2002) The use of LH activity to drive folliculogenesis: Exploring uncharted territories in ovulation induction. Hum Reprod Update 8,543-557.
7. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT, Jr., Schoolcraft W et al (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75,38-45.
8. Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C and Pellicer A (2001) Human ovarian steroid secretion in vivo: Effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 16,2533-2539.
9. Hohmann FP, Macklon NS and Fauser BC (2003) A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88,166-173.
10. Kelly MP, Shapiro D, Tillotson D and Batzer F (2002) Clinical outcomes and cycle characteristics of donor oocyte cycles using the GnRH analogues ganirelix or leuprolide. Fertil Steril 78(3 Suppl 1), S118-S119, Abstract P-10.
11. Kenigsberg D, Brenner S and Nee G (2002) Initial experience with a GnRH antagonist in good prognosis patients undergoing IVF treatment. Abstract P-1. Fertil Steril 77(4 Suppl 3), S12-S13.
12. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004) Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 82,102-107.
13. Meldrum D, Scott R, Levy MJ, Alper M and Noyes N (2002) A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles. Fertil Steril 78(3 Suppl 1), S176, Abstract P-182.
14. Obruca A, Fischl F and Huber J (2001) Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Abstract O-217. Hum Reprod 16(Suppl 1),89.
15. van Hooren HG, Fischl F, Aboulghar, Mares, Nicollet B, Behre HM, van D, V, Simon A, Kilani Z, Barri PN et al (2001) Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16,644-651.
16. Van Loenen ACD, Pirard C, Donnez J, Huirne AF, Schats R and Lambalk CB (2002) Recombinant follicle stimulating hormone (R-FSH) versus recombinant luteinizing hormone (R-LH) and R-FSH treatment in combination with cetrorelix after oral contraceptive programming in IVF/ ICSI: A feasibility study. Fertil Steril 78(3 Suppl 1), S46, Abstract O-119.
17. WHO Scientific Group (1973) Agents stimulating gonadal function in human. World Health Organization, Geneva.